Cannara Biotech Inc.
TSXV:LOVE.V
0.96 (CAD) • At close March 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 81.748 | 57.26 | 35.841 | 17.02 | 2.551 | 2.097 | 0.433 |
| Cost of Revenue
| 51.961 | 30.029 | 18.51 | 6.724 | 1.326 | 0.404 | 0.274 |
| Gross Profit
| 29.787 | 27.231 | 17.331 | 10.297 | 1.224 | 1.693 | 0.159 |
| Gross Profit Ratio
| 0.364 | 0.476 | 0.484 | 0.605 | 0.48 | 0.807 | 0.368 |
| Reseach & Development Expenses
| 1.121 | 1.031 | 1.257 | 1.907 | 2.601 | 0 | 0 |
| General & Administrative Expenses
| 12.972 | 10.611 | 8.589 | 6.164 | 8.064 | 10.584 | 1.595 |
| Selling & Marketing Expenses
| 6.675 | 2.909 | 1.437 | 1.141 | 0.905 | 0.766 | 0.271 |
| SG&A
| 19.648 | 13.52 | 10.027 | 7.305 | 8.969 | 11.35 | 1.867 |
| Other Expenses
| -1.06 | 0.792 | 1.072 | 0.786 | 1.584 | 0.566 | 0.11 |
| Operating Expenses
| 19.709 | 15.343 | 12.356 | 9.997 | 13.154 | 11.916 | 1.976 |
| Operating Income
| 10.078 | 11.888 | 3.672 | 0.193 | -11.929 | -10.223 | -1.817 |
| Operating Income Ratio
| 0.123 | 0.208 | 0.102 | 0.011 | -4.677 | -4.875 | -4.2 |
| Total Other Income Expenses Net
| -5.594 | -4.942 | -2.635 | -1.785 | -1.165 | -2.749 | -0.296 |
| Income Before Tax
| 4.484 | 6.945 | 2.305 | -1.528 | -13.094 | -12.972 | -2.113 |
| Income Before Tax Ratio
| 0.055 | 0.121 | 0.064 | -0.09 | -5.133 | -6.186 | -4.884 |
| Income Tax Expense
| -1.955 | 0 | -0.551 | 1.566 | 0.714 | 0.856 | 0.296 |
| Net Income
| 6.438 | 6.945 | 2.305 | -3.094 | -13.808 | -13.828 | -2.409 |
| Net Income Ratio
| 0.079 | 0.121 | 0.064 | -0.182 | -5.413 | -6.594 | -5.567 |
| EPS
| 0.072 | 0.078 | 0.026 | -0.04 | -0.19 | -0.2 | -0.035 |
| EPS Diluted
| 0.071 | 0.078 | 0.026 | -0.04 | -0.19 | -0.2 | -0.035 |
| EBITDA
| 15.164 | 15.771 | 9.54 | 3.224 | -9.148 | -10.874 | -1.68 |
| EBITDA Ratio
| 0.186 | 0.275 | 0.266 | 0.189 | -3.586 | -5.185 | -3.884 |